杭州安旭生物科技股份有限公司2025年年度业绩预告

Group 1: 2025 Annual Performance Forecast - The company expects a net profit attributable to shareholders of 71 million to 85 million yuan for 2025, a decrease of 10,729.53 million to 12,129.53 million yuan compared to the previous year, representing a year-on-year decline of 55.80% to 63.08% [1] - The forecasted net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be between 13 million and 15.6 million yuan, a decrease of 2,229.79 million to 2,489.79 million yuan compared to the previous year, reflecting a year-on-year decline of 58.84% to 65.70% [1] Group 2: Previous Year Performance - In the previous year, the total profit was 21,064.01 million yuan, with a net profit attributable to shareholders of 19,229.53 million yuan and a net profit after deducting non-recurring gains and losses of 3,789.79 million yuan [2] Group 3: Reasons for Performance Changes - The company's main business remains stable, but increased strategic investments in new technology platforms and expansion in domestic and international markets have led to higher costs. Additionally, U.S. tariffs have reduced orders in certain regions, contributing to increased operating costs and a decline in profits due to exchange rate fluctuations, reduced interest income, and asset depreciation [4] Group 4: Fundraising Project Delay - The company has decided to postpone the completion date of the "in vitro diagnostic reagents and diagnostic instruments R&D and production project" from January 2026 to January 2027, without changing the investment content or total amount [9][10] - The delay is due to construction progress being slowed by global respiratory infectious diseases, affecting internal and external renovations, and the need for further payments related to the project [11][12] - The postponement is a prudent decision based on the actual situation of the project and will not adversely affect the company's normal operations or long-term development plans [12]